KNSA
KiniksaยทNASDAQ
--
--(--)
--
--(--)
KNSA Profile
Kiniksa Pharmaceuticals International, Plc
A company that developing drugs for recurrent pericarditis and cardiovascular disease
23 Old Bond Street, Floor 3, London, WIS 4PZ, England, United Kingdom
--
Kiniksa Pharmaceuticals International, plc was established in Bermuda on July 21, 2015. The company changed its registration from Bermuda to the United Kingdom on June 28, 2024. The Company is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic drugs for patients with debilitating diseases with serious unmet medical needs. The company's immunomodulatory combinations ARCALYST, KPL-404 and mavrilimumab target a range of undertreated cardiovascular and autoimmune diseases based on strong biological principles or proven mechanisms, and offer the potential for differentiation.
